神州細胞-U股票討論區

Despite impressive revenue growth, the company's forecast growth is lower than the industry, not justifying its high P/S ratio. Many investors remain bullish, unwilling to sell their stock. However, unless conditions improve, the high P/S ratio is seen as unreasonable.

Analysts expect Chinese Biotechs to break even in over a year, but could be delayed if growth slows. The firm's current negative equity is a significant issue.